Core Insights - TG Therapeutics has secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital, allowing for a net raise of $500 million in non-dilutive capital after repaying an existing $250 million facility [1][3] - The company has increased its share repurchase program from $100 million to $300 million, having repurchased approximately $38 million of common stock at an average price of $28.98 per share as of March 18, 2026 [2] Financial Position - The new credit facility enhances the financial position of TG Therapeutics with improved terms compared to the previous facility, providing substantial non-dilutive capital to support share repurchases and business development [3] - The total facility size can reach up to $1 billion, contingent upon mutual agreement between TG and Blue Owl [1] Strategic Initiatives - The expansion of the share repurchase program reflects the company's confidence in its business and commitment to long-term shareholder value [3] - TG Therapeutics continues to demonstrate strong commercial execution with its product BRIUMVI and maintains a disciplined approach to growth [3] Product Information - BRIUMVI is a novel monoclonal antibody targeting CD20-expressing B-cells, indicated for the treatment of adults with relapsing multiple sclerosis (RMS) [4][5] - The drug is designed to efficiently deplete B-cells at low doses through a process called glycoengineering [4] Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI approved for RMS in the U.S. and several other countries [27] - The company aims to advance its pipeline while supporting the growth of BRIUMVI through strategic financial maneuvers [3][27]

On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics (NASDAQ:TGTX), acquiring 268,875 shares worth $8,015,164. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, ACT Capital Management established a new position in TG Therapeutics during the prior quarter, acquiring 268,875 shares. The quarter-end value of the stake stood at $8,015,164, reflecting the full impact of the new holding’s valuation. What else to know ...

Core Insights - TG Therapeutics Inc. (NASDAQ:TGTX) is recognized as one of the 10 most shorted biotech stocks to buy according to hedge funds [1] - The company reported Q4 revenue of $192.6 million, slightly below consensus estimates of $193.3 million [1] - CEO Michael Weiss highlighted 2025 as a promising year for TG Therapeutics, particularly due to the momentum surrounding BRIUMVI [1] Financial Performance - The company experienced significant year-over-year growth both in the U.S. and globally, attributed to increased adoption and availability of its products [2] - TG Therapeutics is advancing its late-stage clinical programs and strengthening its financial foundation as it approaches 2026 [2] - The company is focused on delivering value to patients, healthcare providers, and shareholders through disciplined business operations and good financial guidance [2] Product Development - BRIUMVI is a key product for TG Therapeutics, aimed at transforming the treatment landscape for B-cell mediated diseases, including multiple sclerosis [5][6] - The company specializes in acquiring, developing, and commercializing innovative therapies to improve patient outcomes and quality of life [5][6] Analyst Insights - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while maintaining an Overweight rating, indicating an upside potential of over 57% [4]

Core Insights - TG Therapeutics announced significant efficacy results for BRIUMVI (ublituximab-xiiy) in treating highly active relapsing multiple sclerosis (RMS) based on a post hoc pooled analysis of Phase 3 ULTIMATE I and II studies [1][2] Group 1: Efficacy Results - The analysis included 168 participants with highly active disease, showing BRIUMVI reduced the annualized relapse rate (ARR) to 0.145 compared to 0.496 for teriflunomide, a 70.8% relative reduction (P<0.001) [6] - At Week 12, BRIUMVI reduced the least squares mean number of gadolinium-enhancing (Gd+) T1 lesions by 83.3% compared to teriflunomide (0.114 vs 0.683; P<0.001) [6] - Over 96 weeks, Gd+ T1 lesions were reduced by 95.6% with BRIUMVI versus teriflunomide (0.038 vs 0.875; P<0.001) [6] - NEDA-3 rates at Week 12 were 29.5% for BRIUMVI versus 10.1% for teriflunomide, indicating a 4.8-fold higher likelihood of achieving NEDA-3 with BRIUMVI during Weeks 24-96 (77.9% vs 16.4%; P<0.001) [6] Group 2: Study Design and Population - ULTIMATE I and II trials were randomized, double-blind, and included 1,094 patients across 10 countries, with participants receiving either BRIUMVI or teriflunomide for 96 weeks [5][8] - Patients had to have experienced at least one relapse in the previous year or had a T1 gadolinium-enhancing lesion, with an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline [5] Group 3: Company Overview - TG Therapeutics is focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI approved for various forms of RMS [8][10] - The company emphasizes the importance of early, high-efficacy treatment for patients with aggressive disease, as highlighted by the study results [2][3]

Market Overview - Equity markets are experiencing volatility due to geopolitical uncertainties and elevated interest rates, which are unfavorable for investors accustomed to ultra-low rates [1] - Companies that can fund their own growth through profits rather than relying on external financing are becoming increasingly important in the current economic environment [1] Investment Strategy - BlackRock has recommended focusing on high-quality income and durable growth opportunities, suggesting that the current market presents a unique chance since the Global Financial Crisis [2] - Durable growth in a high-interest environment is associated with companies that exhibit healthy profitability, leading to a search for profitable growth stocks that do not require high-interest financing [3] Methodology for Stock Selection - A list of 13 profitable growth stocks was compiled, focusing on companies with a market cap of at least $2 billion and expected revenue growth of at least 30% over the next year [5] - The stocks were sorted by net profit and are also favored by hedge funds, indicating strong market interest [5][6] Company Highlights ARMOUR Residential REIT, Inc. (NYSE:ARR) - Reported Q4 fiscal 2025 net income of $208.7 million, or $1.86 per share, with net interest income of $50.4 million [7] - Raised $3.8 million through preferred stock and $138 million through common stock, issuing approximately 7.5 million common shares [8] - Distributed dividends of $0.24 per common share monthly, totaling $0.72 for the quarter, with management expressing confidence in the company's strategy and dividend outlook for 2026 [9][10] TG Therapeutics, Inc. (NASDAQ:TGTX) - Reported Q4 net income of $23 million, contributing to a full-year net income of $447.2 million, with total global revenue of $616 million for 2025 [13] - Operating expenses for the year were approximately $328 million, projected to rise to $350 million in 2026, plus an additional $100 million for manufacturing and start-up activities [14] - The company expects U.S. revenue to grow sequentially in Q1 to approximately $185 million to $190 million [14] Gildan Activewear Inc. (NYSE:GIL) - Reported Q4 revenue of $1.08 billion, a 31.4% year-over-year increase, and Non-GAAP EPS of $0.96, slightly above estimates [17] - Operating cash flows increased by 59.8%, and free cash flows rose by 46.4% year-over-year [17] - Returned $33 million to shareholders through dividends and share repurchases, with a 10% dividend increase announced for 2026 [18]

Core Insights - TG Therapeutics, Inc. announced the schedule for presentations on BRIUMVI® (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis (RMS) at the AAN 2026 annual meeting [1][2] Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI® approved for treating adult patients with RMS in the U.S. and several other countries [27] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [3] - The product is indicated for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [4] Clinical Studies and Presentations - Upcoming presentations include data from the ENABLE Phase 4 observational study and updates from the ENHANCE study regarding the safety and tolerability of a modified dosing regimen [2][6] - The presentations will take place on April 21, 2026, during the AAN annual meeting [6] Safety Information - BRIUMVI has contraindications for patients with active Hepatitis B virus infection and a history of life-threatening infusion reactions [5][7] - Infusion reactions occurred in 48% of patients treated with BRIUMVI, with serious reactions in 0.6% of patients [5] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [9] Market Context - Relapsing multiple sclerosis (RMS) affects nearly 1 million people in the U.S., with approximately 85% initially diagnosed with relapsing-remitting multiple sclerosis [26]

Core Viewpoint - Precision BioSciences, Inc. has achieved a clinical milestone related to its license agreement with TG Therapeutics, Inc. for the development of azercabtagene zapreleucel (azer-cel) in a Phase 1 clinical trial [1] Group 1: Company Achievements - The milestone payment was triggered by the progress of the Phase 1 clinical trial of azer-cel, indicating advancement in the clinical development of this gene editing therapy [1]

Core Insights - TG Therapeutics, Inc. (NASDAQ:TGTX) is identified as a promising investment opportunity in the biotech sector, particularly due to its financial performance and product growth [1][2]. Financial Performance - For fiscal Q4 2025, TG Therapeutics reported total revenue of $192.6 million, with full-year revenue reaching $616.3 million [1]. - The U.S. net product revenue for BRIUMVI was $182.7 million in Q4 2025, marking a quarterly growth of approximately 20% year-over-year, and $594.1 million for the full year, reflecting a year-over-year increase of about 92% [1]. Product Expansion - The company has expanded the commercialization of BRIUMVI outside the United States through its partnership with Neuraxpharm, with approvals in regions such as the European Union, United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates [2]. - For the full year 2026, TG Therapeutics aims for total global revenue between $875 million and $900 million, with U.S. net product revenue for BRIUMVI projected at approximately $825 million to $850 million [2]. Product Portfolio - TG Therapeutics is focused on the acquisition, development, and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases, with a product portfolio that includes TG-1501, TG-1701, Ublituximab, and Umbralisib [3].

Financial Performance - TG Therapeutics generated net product revenue of approximately $606.9 million for the year ended December 31, 2025, compared to $313.7 million for 2024, reflecting a significant increase in market penetration of BRIUMVI in the U.S. and sales to Neuraxpharm [436]. - The total revenue for 2025 was $616.3 million, an increase of $287.3 million from $329.0 million in 2024 [446]. - The net income for 2025 was $447.2 million, a substantial increase from $23.4 million in 2024, primarily due to higher product revenues and an income tax benefit [446]. - License, milestone, royalty and other revenue decreased to $9.4 million for the year ended December 31, 2025, down from $15.3 million in 2024, primarily due to a significant one-time milestone payment in 2024 [447][448]. - Total revenue for the year ended December 31, 2024 was $329.0 million, a 40.8% increase from $233.7 million in 2023, driven by higher product revenue from BRIUMVI [458]. Expenses - The cost of revenue increased to $100.7 million in 2025 from $38.5 million in 2024, indicating higher expenses associated with the commercialization of BRIUMVI [446]. - Research and development expenses rose to $160.2 million in 2025, up from $94.3 million in 2024, driven by increased clinical and manufacturing costs [446]. - Selling, general, and administrative expenses totaled $232.0 million in 2025, compared to $154.3 million in 2024, reflecting the costs associated with expanding the commercial organization [446]. - Other research and development expenses rose to $143.6 million for the year ended December 31, 2025, up from $83.1 million in 2024, due to increased clinical trial expenses and manufacturing costs [452]. - Noncash compensation expense for research and development increased to $16.6 million in 2025 from $11.2 million in 2024, reflecting higher performance-based awards [450]. - Other selling, general and administrative expenses increased to $184.0 million in 2025 from $122.9 million in 2024, primarily due to marketing and personnel costs associated with BRIUMVI commercialization [454]. Cash Flow and Financing - Net cash used in operating activities improved to $24.8 million in 2025 from $40.5 million in 2024, reflecting higher net income and favorable working capital changes [475][476]. - Net cash provided by investing activities for the year ended December 31, 2025 was $13.8 million, a significant increase from $1.0 million used in 2024 [478]. - Net cash used in financing activities for the year ended December 31, 2025 was approximately $89.7 million, compared to net cash provided of $128.5 million in 2024, primarily due to stock repurchase [479]. - The Initial Term Loan of $250 million was entered into on August 2, 2024, with a maturity date of August 2, 2029, and requires quarterly amortization payments of $12.5 million starting June 30, 2028 [483]. - Total financing and upfront costs related to the Initial Term Loan were $6.0 million, recorded as debt issuance costs and debt discount costs [488]. - Amortization of debt issuance and debt discount costs was $1.2 million, $2.0 million, and $2.4 million for the years ended December 31, 2025, 2024, and 2023, respectively [488]. Regulatory and Market Risks - The company’s product BRIUMVI is subject to regulatory approvals and market acceptance, which are critical for revenue generation [15]. - The company may experience unfavorable pricing regulations or reimbursement policies that could harm its business [20]. - The company is subject to various risks related to governmental regulation and compliance, which could adversely affect its operations [20]. - The company has faced significant competition, which may impact its ability to commercialize drugs successfully [20]. - The company relies on third parties for clinical trials and manufacturing, increasing the risk of delays or inability to obtain regulatory approval [25]. Future Outlook - The company anticipates that existing cash and projected future revenues will be sufficient to fund operations for more than twelve months following the report date [437]. - The company may need to raise additional capital, which could delay or limit drug development programs or commercialization efforts [20]. - The company has incurred substantial operating losses since inception and may continue to do so in the future [20]. - The company’s financial performance is subject to fluctuations in the trading price of its common stock [24]. - The company’s ability to protect its intellectual property is crucial for maintaining a competitive edge in the market [25]. - As of December 31, 2025, the company was in compliance with all financial covenants related to the Initial Term Loan [485].

Group 1 - The article discusses TG Therapeutics (TGTX) and its potential growth in the multiple sclerosis (MS) market with the product Azer-Cel [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - Biotech Analysis Central offers a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to TG Therapeutics or its products [1][3][4]